Benitec Biopharma announced positive 24-month follow-up results from its BB-301 gene therapy clinical trial for oculopharyngeal muscular dystrophy (OPMD). Patient 1 demonstrated deepening improvements in swallowing function with 60% reduction in post-swallow residue and 78% improvement in dysphagic symptom burden at 24 months. All four patients who completed the 12-month follow-up period met responder criteria, showing durable response to the treatment.

Benitec Biopharma reported positive Phase 1b/2a trial results for BB-301, a gene therapy targeting Oculopharyngeal Muscular Dystrophy (OPMD), with a 100% responder rate. The FDA granted Fast Track Designation, and the company raised $100 million to advance the therapy's development.

Benitec Biopharma will provide an update on its Phase 1b/2a clinical study for BB-301, a gene therapy treatment for Oculopharyngeal Muscular Dystrophy, focusing on results from six patients in Cohort 1.

Benitec Biopharma announced the acceptance of a late-breaking oral abstract for the BB-301 Phase 1b/2a clinical study in Oculopharyngeal Muscular Dystrophy (OPMD) patients. Interim clinical study updates for the first three subjects will be presented at the Muscular Dystrophy Association Clinical and Scientific Conference in March 2025.

The global RNA-based therapeutic market is expected to grow from $9.46 billion in 2025 to $40.81 billion by 2034, driven by the rising prevalence of genetic disorders and the demand for personalized medicine. North America and Asia Pacific are the key regional markets.

Benitec Biopharma reported positive data from two subjects treated with low-dose BB-301 in a Phase 1b/2a study for Oculopharyngeal Muscular Dystrophy (OPMD). The subjects experienced durable, clinically meaningful improvements in swallowing, with one subject achieving a clinically normal swallowing profile.

Benitec Biopharma reported positive 90-day and 180-day interim clinical data for the first subject dosed with the low-dose of BB-301 in the Phase 1b/2a study for Oculopharyngeal Muscular Dystrophy (OPMD). The company also dosed a second subject and expects to dose a third subject in Q4 2024. Benitec closed a $40 million private placement financing, extending its cash runway through 2025.

Benitec Biopharma announced that a late-breaking abstract on its BB-301 gene therapy for oculopharyngeal muscular dystrophy (OPMD) has been accepted for oral presentation at the 29th Annual Congress of the World Muscle Society.

Benitec Biopharma reports continued improvements in swallowing function for the first subject treated with low-dose BB-301 in its OPMD Phase 1b/2a study, as measured by radiographic assessments and subject-reported outcomes at the 180-day timepoint.

-Positive Interim Clinical Trial Data for the First Oculopharyngeal Muscular Dystrophy (OPMD) Subject Dosed with BB-301 in the Phase 1b/2a Clinical Treatment Study Reported in April-

-First efficacy signals demonstrated for a gene therapy under development for Oculopharyngeal Muscular Dystrophy (OPMD) which affects ~15,000 patients worldwide-

HAYWARD, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference (“ddRNAi”) platform, today announced a $40.0 million private investment in public equity (PIPE) financing from the sale of 5,749,152 shares of its common stock at a price per share of $4.80, and, in lieu of shares of common stock, pre-funded warrants to purchase up to an aggregate of 2,584,239 shares of its common stock at a price per pre-funded warrant of $4.7999, to certain institutional accredited investors. The oversubscribed financing was led by Suvretta Capital Management, LLC (“Suvretta Capital”) with participation from new and existing investors including Adage Capital Partners L.P., Nantahala Capital, multiple healthcare-focused funds, and a leading mutual fund. Gross proceeds from the PIPE financing total approximately $40.0 million, before deducting offering expenses. The closing price of the Company’s common stock on April 17, 2024 was $4.80.